Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : | NSE Symbol : | ISIN : | Industry : |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
15-Nov-2024	21-Nov-2024	Employee Stock Option	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/11/2024 inter alia to consider and approve the Vivo Bio Employees Stock Option Scheme 2024 (VBESOS 2024) in terms of SEBI (Share Based Employee Benefits and Sweat Equity) regulations 2021. With reference to the above cited subject and our letter dated November 15, 2024, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Thursday, November 21, 2024, inter-alia, transacted the following business: 1. Pursuant to the recommendations of the Nomination and Remuneration Committee ('NRC'), approved the Vivo Bio Employees Stock Option Scheme, 2024 ('VBESOS, 2024') for grant of stock options to eligible Directors and Employees of the Company and its Group Company(ies) including its Subsidiary / Associate Company(ies) (Present and Future, if any), subject to approval of the shareholders of the Company, as per SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ['SEBI (SBEBSE) Regulations, 2021']. The Company shall seek the approval of Members through postal ballot (As per BSE Announcement Dated on 21/11/2024)
29-Oct-2024	14-Nov-2024	Quarterly Results	Quarterly Results Please find enclosed Unaudited Financial Results for the Quarter and Half Year ended September 30, 2024 (As Per BSE Announcement Dated on: 14/11/2024)
26-Aug-2024	26-Aug-2024	AGM	Please find enclosed Outcome of the Board Meeting
01-Aug-2024	10-Aug-2024	Quarterly Results	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30 2024. Please find enclosed Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2024 (As Per BSE Announcement Dated on: 10/08/2024)
18-Jun-2024	18-Jun-2024	Change in Other Executives	With reference to the above cited subject, and pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('Listing Regulations'), and based on the recommendation of the Audit Committee, the Board of Directors of the Company at their meeting held today, i.e. Tuesday, June 18, 2024, inter-alia, transacted the following business: 1. Approved the Notice of Postal Ballot recommending to the shareholders, for appointment of Mr. Viswanath Kompella, Promoter, as an advisor of the company. This is for your information and records.
06-May-2024	20-May-2024	Accounts	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2024 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31 2024. With reference to above cited subject, we bring to your kind notice that the Board of Directors at their meeting held today i.e., Monday, May 20, 2024, inter-alia, Approved the Audited Standalone and Consolidated Financial Results of the company for the fourth quarter and year ended March 31, 2024. (As Per BSE Announcement dated on 20.05.2024)
30-Jan-2024	12-Feb-2024	Quarterly Results	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results for the Third Quarter and Nine Months ended December 31 2023. Please be informed that the trading window of Vivo Bio Tech Limited shall remain closed for all Directors Promoters Designated Employees and Specified Connected Persons of the Company till February 14 2024 in view of the aforesaid Board Meeting. This is for your information and records. With reference to the above cited subject and our letter dated January 30, 2024, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Monday, February 12, 2024, inter-alia, transacted the following business: 1. Approved the Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2023. The meeting commenced at 06.00 p.m. and concluded at 07.15 p.m. This is for your information and records. (As per BSE Announcement Dated on 12/02/2024)
23-Jan-2024	23-Jan-2024	Change in Other Executives	Outcome of the Board Meeting - Intimation of Appointment of Mr. Vaishnavi Kiran Ayinampudi as the Company Secretary & Compliance Officer of the Company
03-Nov-2023	14-Nov-2023	Quarterly Results	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve the Un-Audited Financial Results of the Company for the Second Quarter and Half-Year ended September 30 2023 Vivo Bio Tech Limited has informed the exchange about the Outcome of Board Meeting for Approval Of Un-Audited Standalone & Consolidated Financial Statements Of The Company For The Second Quarter and Half Year Ended September 30, 2023 Vivo Bio Tech Limited has submitted with the exchange the Un-Audited Financial Results of the Company for the second quarter and half year ended September 30, 2023 (As Per BSE Announcement dated on 14.11.2023) Vivo Bio Tech Limited has submitted with the exchange the copies of Newspaper Publication for Un-Audited Financial Results of the Company for the secodn quarter and half-year ended September 30, 2023 (As Per BSE Announcement Dated on 16.11.2023)
17-Sep-2023	21-Sep-2023	Raising funds through Debt Instr.	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2023 inter alia to consider and approve VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2023 inter alia to consider and approve 1. Proposal for issuance of equity shares/warrants by way of a preferential allotment in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act 2013 as amended subject to such regulatory/ statutory approvals as may be required. 2. Convening of an Extra-Ordinary General Meeting or Postal Ballot process to seek approval of the shareholders in respect of the aforesaid proposal of preferential allotment as required. Vivo Bio Tech Limited has informed the exchange that with reference to the Company''s letter dated September 17, 2023, the Board of Directors of the Company at their meeting held today, i.e. Thursday, September 21, 2023, inter-alia, transacted the following business: 1. Approval for engagement/appointment of Consultants or Intermediaries for the proposed issuance of Equity Shares/Warrants by way of a Preferential Allotment, in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, as amended, subject to such regulatory/ statutory approvals as may be required. (As Per BSE Announcement dated on 21.09.2023)
31-Aug-2023	31-Aug-2023	AGM	Vivo Bio Tech Limited has informed the exchange regarding the business items transacted and approved by the Board at its meeting held today i.e. on August 31, 2023
24-Jul-2023	07-Aug-2023	Quarterly Results	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 inter alia to consider and approve Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30 2023 Vivo Bio Tech Limited has submitted with the exchange the outcome of Board Meeting held on August 07, 2023 for Approval of Un-Audited Standalone & Consolidated Financial Statements Of The Company For The Quarter Ended June 30, 2023 Vivo Bio Tech Limited has submitted with the exchange the Un-Audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2023 (As per BSE Announcement Dated on 07/08/2023)
18-May-2023	30-May-2023	Accounts	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the Fourth Quarter and Year Ended March 31 2023 Vivo Bio Tech Limited has submitted with the exchange the Outcome of Board meeting for the item transacted for approval of Audited Standalone & Consolidated Financial Statements of the Company for the fourth quarter and year ended March 31, 2023. Vivo Bio Tech Limited has submitted with the exchange the Audited Standalone & Consolidated Financial Statements of the Company for the fourth quarter and year ended March 31, 2023. (As Per BSE Announcement Dated on 30.05.2023)
30-Jan-2023	13-Feb-2023	Quarterly Results	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve the Un-Audited Standalone & Consolidated Financial Results of the Company for the Quarter and Nine Months ended December 31 2022. Vivo Bio Tech Limited has submitted with the exchange the Outcome of Board meeting for the item transacted for apporval of Un-Audited Standalone & Consolidated Financial Results for the quarter and nine months ended December 31, 2022. (As Per BSE Announcement dated on 13.02.2023)
12-Dec-2022	21-Dec-2022	Preferential Issue	VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/12/2022 inter alia to consider and approve 1. Proposal for issuance of equity shares/warrants by way of a preferential allotment in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act 2013 as amended subject to such regulatory/ statutory approvals as may be required. 2. Convening of an Extra-Ordinary General Meeting or Postal Ballot process to seek approval of the shareholders in respect of the aforesaid proposal of preferential allotment as required. Vivo Bio Tech Limited has informed the exchange that with reference to the Company''s letter dated December 12, 2022, the Board of Directors of the Company at their meeting held today, i.e. Wednesday, December 21, 2022, inter-alia, transacted the following business: 1. Approval for engagement/appointment of Consultants or intermediaries for the proposed issuance of equity shares/warrants by way of a preferential allotment, in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, as amended, subject to such regulatory/ statutory approvals as may be required. (As per BSE Announcement Dated on 21/12/2022)

1 2 3